EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EyePoint Pharmaceuticals reports revenue growth and strategic expansion plans

EyePoint Pharmaceuticals showcased strong revenue growth, promising product pipeline with EYP-1901, and strategic partnerships for future expansion. While facing challenges in trial design and molecule size for sustained release, the company is well-positioned for growth with opportunities for collaborations and improved margins in 2023.

EyePoint Pharmaceuticals reports strong Q1 performance and advances revolutionary eye disease treatment

EyePoint Pharmaceuticals (EYPT) delivered a strong Q1 2023 performance, driven by progress in clinical trials for EYP-1901 and a robust YUTIQ franchise.
The company's focus on innovation, safety, and market needs positions EYP-1901 as a potential game-changer in treating chronic eye diseases.
While challenges exist in trial modifications and regulatory considerations, opportunities abound in market expansion, collaboration potential, and regulatory progress.
Overall, EyePoint Pharmaceuticals (EYPT) showcases promising growth prospects and a commitment to advancing novel treatments for retinal diseases.

EyePoint Pharmaceuticals reports Q2 revenue growth amidst operational challenges

EyePoint Pharmaceuticals' Q2 2023 performance showed revenue growth but with significant operating expenses leading to a net loss.
Strengths lie in the progress of EYP-1901, positive data presentations, and a well-capitalized position for future endeavors.
Challenges include financial losses, concerns about patient response variability, and Phase III trial design complexities.
Opportunities exist in exploring funding avenues, post-approval studies, and strategic cost management for Phase III trials.

EyePoint Pharmaceuticals reports Q3 revenue growth and advances drug pipeline

EyePoint Pharmaceuticals showcased progress in drug development and revenue generation in Q3 2023.
The company is strategically positioned with a strong cash position to fund operations into 2025.
Focus on innovative drug delivery mechanisms and collaborations for sustained release treatments.

EyePoint Pharmaceuticals excels in Q4, poised for retinal disease innovation

EyePoint Pharmaceuticals delivered strong financial results, showcased promising trial outcomes for EYP-1901 in wet AMD, and addressed key analyst inquiries regarding market dynamics and competition. With a focus on innovation and strategic leadership appointments, the company is poised for transformative developments in retinal disease treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR –

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know

EyePoint Pharmaceuticals (EYPT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going

WATERTOWN, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) --  EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 7, 2024 to report its fourth quarter and full-year 2023 financial results and highlight recent corporate developments.

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024

EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care. The company has a strong drug delivery platform with Durasert and has sold off its profitable YUTIQ business. EYP-1901 targets multi-billion dollar markets in wet AMD, NPDR, and DME, but it's not entirely a slam dunk as competition is increasing.

EyePoint Is Betting The Bank On EYP-1901

BellRing Brands Inc

Copart

Financial markets are driven by cycles, and each cycle is accompanied by uptrends and downtrends. In the uptrends, those who have been previously positioned in companies with growth potential, undoubtedly enjoy good returns.

The 3 Most Promising Stocks to Invest in Before They Take Off

Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice

The consensus price target hints at a 31.3% upside potential for EyePoint Pharmaceuticals (EYPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet

WATERTOWN, Mass., Feb. 03, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced results from new subgroup analyses from the Phase 2 DAVIO 2 clinical trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E. These data are being presented in two sessions at the Angiogenesis, Exudation, and Degeneration 2024 Meeting held virtually today, February 3, 2024. The presenting speakers are Charles C. Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas, and Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University.

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that George Elston, Executive Vice President and Chief Financial Officer of EyePoint Pharmaceuticals, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 p.m. ET.

EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dyne Therapeutics

OPKO Health

Evolve Transition Infrastructure LP

STAAR Surgical

VOXX International Corporation Class A

As the year got underway, biotechs were in focus among the notable insider purchases.

New Year's Insider Buying Focuses on Biotechs

WATERTOWN, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the first patient has been dosed in the Phase 2 VERONA clinical trial of EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema

WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 10:30 a.m. PT/1:30 p.m. ET.

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Ford Motor Company

Lovesac Company

Madrigal Pharmaceuticals

Occidental Petroleum

Prudential Financial

RumbleON

Terex

From executives to beneficial owners, insiders are increasingly stepping up to the buy window as we approach the end of the year.

Huge Warren Buffett Purchase Highlights Hot Insider Buying

A biotech company with recent encouraging trial results and a public offering of shares prompted reactions from insiders and a beneficial owner.

What Has Insiders Eyeing This Biotech Stock

EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?

The average of price targets set by Wall Street analysts indicates a potential upside of 77.1% in EyePoint Pharmaceuticals (EYPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to Trade

If you are looking for stocks that are well positioned to maintain their recent uptrend, EyePoint Pharmaceuticals (EYPT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'

EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%.

EyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Data

EyePoint Pharmaceuticals (NASDAQ: EYPT) stock price has surged hard this week as it became a favorite among StockTwits traders. The shares jumped to a high of $22.40 on Monday, its highest point since November 2019.

EyePoint (EYPT) stock price went parabolic: brace for a pullback

EyePoint Pharmaceuticals Inc. EYPT, +177.46% announced Monday afternoon that it has begun an underwritten public offering of $175 million in common stock. The company will also give underwriters the chance to purchase up to an additional $26.25 million of stock at the offering price, for 30 days, less an underwriting discount.

EyePoint announces $175 million stock offering following record surge in share price

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) shares surged 176% to $18.24 in midday trading on Monday after the therapeutics developer announced positive results from a Phase 2 trial of its EYP-1901 treatment for wet age-related macular degeneration, or wet-AMD.  EyePoint said the clinical trial met its primary endpoint, in addition to key secondary endpoints, while maintaining a favorable safety profile with no ocular or systemic serious adverse events.

Eyepoint Pharmaceuticals stock soars on wet-AMD trial results

EyePoint Pharmaceuticals (NASDAQ: EYPT ) stock is rocketing higher on Monday thanks to the company's latest clinical trial results for EYP-1901. A Phase 2 clinical trial of EYP-1901 includes positive topline results for the drug as a sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD).

Why Is EyePoint Pharmaceuticals (EYPT) Stock Up 187% Today?

Advanced Micro Devices

EyePoint Pharmaceutics Inc.'s stock EYPT, +5.76% rocketed 362% early Monday, after the company announced positive results from a Phase 2 trial of its EYP-1901 treatment for wet age-related macular degeneration, or wet AMD. The company said the study combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E, met its primary endpoint as well as key secondary endpoints with both doses used in the study, including a more than 80% reduction in treatment burden, nearly two-thirds of eyes supplement-free up to six months and over 80% receiving only zero or one supplement up to six-months.

EyePoint Pharmaceuticals' stock soars 362% after company announces positive data from trial of wet AMD treatment

– Both EYP-1901 cohorts demonstrated a statistically non-inferior change in BCVA versus aflibercept control with a numerical difference of only -0.3 and -0.4 letters, respectively for the 2 mg and 3 mg dose at blended six-month endpoint –

EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpoints

News for EyePoint Pharmaceuticals Stock (EYPT)